Drugs / Tris-CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05577091 | Sep 2023 → Nov 2024 overdue | glioblastoma | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tris-CAR-T | “T cells will be isolated from the PBMC sample and then be bioengineered into a 4th generation CAR-T cell, Tris-CAR-T cells.” NCT05577091 ↗ |
| Modality | Cell therapy | “T cells will be isolated from the PBMC sample and then be bioengineered into a 4th generation CAR-T cell, Tris-CAR-T cells.” NCT05577091 ↗ |
| Route | Other | “Intratumoral or intraventricular administration via Ommaya reservoir.” NCT05577091 ↗ |
| Target | CD44 | “The autologous Tris-CAR-T cell, targeting both CD44 and CD133, the two inverse correlated targets, introduced truncated IL7Ra to the intracellular domain of the CAR molecule,...” NCT05577091 ↗ |